Retrospective study of post-treatment 131I SPECT/CT imaging for personalizing therapy of patients with differentiated thyroid cancer

Introduction: The absence of anatomical landmarks in the whole body scan makes it challenging to precisely localize 131I uptake, which is used to treat patients with differentiated thyroid cancer (DTC). Recently, SPECT/CT studies have been utilized to increase the diagnostic sensitivity and specific...

Full description

Saved in:
Bibliographic Details
Main Authors: Sonya Sergieva, Teodor Sofiyanski, Bozhil Robev, Milena Dimcheva, Albena Fakirova
Format: Article
Language:English
Published: Pensoft Publishers 2024-12-01
Series:Folia Medica
Online Access:https://foliamedica.bg/article/139177/download/pdf/
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841556476540223488
author Sonya Sergieva
Teodor Sofiyanski
Bozhil Robev
Milena Dimcheva
Albena Fakirova
author_facet Sonya Sergieva
Teodor Sofiyanski
Bozhil Robev
Milena Dimcheva
Albena Fakirova
author_sort Sonya Sergieva
collection DOAJ
description Introduction: The absence of anatomical landmarks in the whole body scan makes it challenging to precisely localize 131I uptake, which is used to treat patients with differentiated thyroid cancer (DTC). Recently, SPECT/CT studies have been utilized to increase the diagnostic sensitivity and specificity. Aim: To evaluate the clinical role of post-treatment 131I SPECT/CT imaging in the management of DTC. Materials and methods: The study included 564 patients (384 women and 180 men) aged 12 to 83 years with DTC referred to our hospital between 2011 and 2021. A post therapeutic 131I whole-body scintigraphy (WBS) with SPECT/CT imaging was performed. Results: 370 (65%) cases with papillary carcinoma, 101 (18%) cases with follicular carcinoma, and 93 (17%) cases with follicular variant of papillary DTC were histologically proven. 131I WBS was positive in 423 (75%) cases. SPECT/CT showed thyroid remnant in 237 (42%) patients, tumor persistence – in 15 (2.7%), and local recurrence in the thyroid bad in 17 (3%) cases. Enlarged cervical and mediastinal lymph nodes were visualized in 141 (25%) cases. Forty-eight (8.5%) patients had pulmonary metastases, 14 had osteolytic bone lesions and 6 (1.4%) had brain metastases detected on the SPECT/CT images. Negative 131I SPECT/CT data influenced significantly the clinical management of a large cohort with recurrent and metastatic DTC, leading to rejection of radioiodine treatment as a therapeutic alternative. Conclusion: SPECT/CT improved the 131I WBS accuracy, thus changing the management of DTC determining indications for surgery, the need to give or withhold 131I therapy, and selecting cases for radiotherapy or chemotherapy in order to personalize the treatment.
format Article
id doaj-art-1bcc8d6bc68741c7aa30608b51e67a39
institution Kabale University
issn 1314-2143
language English
publishDate 2024-12-01
publisher Pensoft Publishers
record_format Article
series Folia Medica
spelling doaj-art-1bcc8d6bc68741c7aa30608b51e67a392025-01-07T08:30:08ZengPensoft PublishersFolia Medica1314-21432024-12-0166677678610.3897/folmed.66.e139177139177Retrospective study of post-treatment 131I SPECT/CT imaging for personalizing therapy of patients with differentiated thyroid cancerSonya Sergieva0Teodor Sofiyanski1Bozhil Robev2Milena Dimcheva3Albena Fakirova4Tokuda HospitalTokuda HospitalSt Ivan Rilski University HospitalSofia Cancer Center LtdMilitary Medical AcademyIntroduction: The absence of anatomical landmarks in the whole body scan makes it challenging to precisely localize 131I uptake, which is used to treat patients with differentiated thyroid cancer (DTC). Recently, SPECT/CT studies have been utilized to increase the diagnostic sensitivity and specificity. Aim: To evaluate the clinical role of post-treatment 131I SPECT/CT imaging in the management of DTC. Materials and methods: The study included 564 patients (384 women and 180 men) aged 12 to 83 years with DTC referred to our hospital between 2011 and 2021. A post therapeutic 131I whole-body scintigraphy (WBS) with SPECT/CT imaging was performed. Results: 370 (65%) cases with papillary carcinoma, 101 (18%) cases with follicular carcinoma, and 93 (17%) cases with follicular variant of papillary DTC were histologically proven. 131I WBS was positive in 423 (75%) cases. SPECT/CT showed thyroid remnant in 237 (42%) patients, tumor persistence – in 15 (2.7%), and local recurrence in the thyroid bad in 17 (3%) cases. Enlarged cervical and mediastinal lymph nodes were visualized in 141 (25%) cases. Forty-eight (8.5%) patients had pulmonary metastases, 14 had osteolytic bone lesions and 6 (1.4%) had brain metastases detected on the SPECT/CT images. Negative 131I SPECT/CT data influenced significantly the clinical management of a large cohort with recurrent and metastatic DTC, leading to rejection of radioiodine treatment as a therapeutic alternative. Conclusion: SPECT/CT improved the 131I WBS accuracy, thus changing the management of DTC determining indications for surgery, the need to give or withhold 131I therapy, and selecting cases for radiotherapy or chemotherapy in order to personalize the treatment.https://foliamedica.bg/article/139177/download/pdf/
spellingShingle Sonya Sergieva
Teodor Sofiyanski
Bozhil Robev
Milena Dimcheva
Albena Fakirova
Retrospective study of post-treatment 131I SPECT/CT imaging for personalizing therapy of patients with differentiated thyroid cancer
Folia Medica
title Retrospective study of post-treatment 131I SPECT/CT imaging for personalizing therapy of patients with differentiated thyroid cancer
title_full Retrospective study of post-treatment 131I SPECT/CT imaging for personalizing therapy of patients with differentiated thyroid cancer
title_fullStr Retrospective study of post-treatment 131I SPECT/CT imaging for personalizing therapy of patients with differentiated thyroid cancer
title_full_unstemmed Retrospective study of post-treatment 131I SPECT/CT imaging for personalizing therapy of patients with differentiated thyroid cancer
title_short Retrospective study of post-treatment 131I SPECT/CT imaging for personalizing therapy of patients with differentiated thyroid cancer
title_sort retrospective study of post treatment 131i spect ct imaging for personalizing therapy of patients with differentiated thyroid cancer
url https://foliamedica.bg/article/139177/download/pdf/
work_keys_str_mv AT sonyasergieva retrospectivestudyofposttreatment131ispectctimagingforpersonalizingtherapyofpatientswithdifferentiatedthyroidcancer
AT teodorsofiyanski retrospectivestudyofposttreatment131ispectctimagingforpersonalizingtherapyofpatientswithdifferentiatedthyroidcancer
AT bozhilrobev retrospectivestudyofposttreatment131ispectctimagingforpersonalizingtherapyofpatientswithdifferentiatedthyroidcancer
AT milenadimcheva retrospectivestudyofposttreatment131ispectctimagingforpersonalizingtherapyofpatientswithdifferentiatedthyroidcancer
AT albenafakirova retrospectivestudyofposttreatment131ispectctimagingforpersonalizingtherapyofpatientswithdifferentiatedthyroidcancer